Smith & Nephew PLC (LSE:SN.) - Share price


Stock Report

Smith & Nephew PLC SN.

Last Price
GBX1,660.50

Day Change
-9.00|-0.54%

As of 22/05/2020
18:42:52 BST | GBX
Minimum 15 Minutes Delay.

Last Close1,669.50p
Day Range1,637.50 - 1,680.76
Mkt Cap14.53Bil
52-Wk Range1,055.01 - 2,023.00
Yield %1.81
ISINGB0009223206
Volume2,650,973
P/E29.85
P/S2.83
P/CF12.47

Share Price

Total Returns 22/05/2020

 Chg (%)  
More ...
Smith & Nephew PLC7.30 
FTSE 100 TR GBP4.33
 
Financials
201720182019
More ...
Income Statement
Turnover4,765.004,904.005,138.00
Operating Profit940.00997.00990.00
Net Profit767.00663.00600.00
Reported EPS0.880.760.68
Balance Sheet
Current Assets2,731.003,077.003,219.00
Non Current Assets5,135.004,982.006,080.00
Total Assets7,866.008,059.009,299.00
Current Liabilities1,346.001,465.001,564.00
Total Liabilities---
Total Equity4,644.004,874.005,141.00
Cash Flow
Operating Cash Flow1,225.001,056.001,318.00
Net Change in Cash113.00182.00-76.00

Regulatory News

DateAuthor Headline
16/08/2017Emma Simon Investor Views: "I’ve Doubled My Money in Utility Shares"
Retired investor Gordon Pope began buying shares in the 1980s and hopes his portfolio will supplement his pension income
24/07/2017Emma Wall 5 Undervalued UK Stock Picks
The Morningstar Fair Value Estimate tells investors what the long-term, intrinsic value of a stock is. So which UK stocks are trading at less than their fair value?
02/02/2017Karen Kwok UK Pharma Stocks Fall as Trump Repeals Obamacare
UK healthcare companies have lost value after Trump signed an executive order last month to repeal the Affordable Care Act, also known as Obamacare
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
14/05/2020PurchaseMr. Roland Daniel Diggelmann1,510.001662,507.00
14/05/2020PurchaseMr. Roland Daniel Diggelmann1,510.5052785.00
14/05/2020PurchaseMr. Roland Daniel Diggelmann1,511.001,04815,835.00
14/05/2020PurchaseMr. Roland Daniel Diggelmann1,510.002914,394.00

Company Profile

Smith & Nephew PLC designs, manufactures, and markets orthopedic devices and wound-care solutions. Its products include knee replacements, hip implants, nails, fixation devices, arthroscopy tools and others.

Sector

Medical Devices

Index

FTSE 100 ,FTSE 350 ,FTSE All Share ,FTSE Eurotop 300 ,FTSE techMARK Focus

Next Event 29/07/2020

Half-Yearly Results
Ratios
Comp
More ...
PER (E)28.40
Div Yld (E)1.94
PEG (E)1.21
ROCE10.47
Op Mrgn0.19
EPS Grwth-0.05
Dividends
PreviousLatest
More ...
Record Date04/10/1903/04/20
Ex-Div03/10/1902/04/20
Paid30/10/1906/05/20
Amnt11.5018.66
Directors
More ...
Non-Executive DirectorMarc E. Owen
Non-Executive DirectorErik Engstrom
Non-Executive Director, Senior Independent Non-Executive DirectorRobin A D Freestone
Non-Executive Director, ChairmanMr. Roberto Quarta
Non-Executive DirectorAngie Risley
Non-Executive DirectorRt. Hon Baroness Virginia Bottomley of Nettlestone PC DL
Non-Executive DirectorMs. Vinita Bali
Executive Director, Chief Executive OfficerMr. Roland Daniel Diggelmann
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2020 Morningstar. All rights reserved.